Hoffmann-la Roche Inc.

Ptc Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Remynd Nv

Ptc Theranentics. Inc.

Hasane Ratni

Mark Rogers-Evans

Caterina Bissantz

Matthias Heinrich Nettekoven

Raffaello Masciadri

Patrick Schnider

Christophe Grundschober

Henner Knust

Anja Limberg

Claus Riemer

Walter Vifian

Roland Jakob-Roetne

Bjoern Bartels

Nikolai A Naryshkin

Marla L Weetall

Emmanuel Pinard

Werner Neidhart

Luke Green

Philippe Jablonski

Bernd Kuhn

Gary Mitchell Karp

Henrietta Dehmlow

Matthew Wright

Narendra Panday

Michael Reutlinger

Soongyu Choi

Hongyan Qi

Jana Narasimhan

Matthew G Woll

Amal Dakka

Ellen Welch

Xiaoyan Zhang

Nanjing Zhang

Gerard Griffioen

Xin Zhao

Xihan Wu

Katrien Princen

Tianle Yang

Anthony A Turpoff

Guido Galley

Bo Han

Rosa Maria Rodriguez Sarmiento

Andreas Koblet

Chang-Sun Lee

Kenichi Kawasaki

Angelique Patiny-Adam

Koen De Witte

Emilie Blanche

Bart De Taeye

Greta Vastakaite

Roger David Norcross

Andrew William Thomas

Guangming Chen

Tanja Schulz-Gasch

Erwin Goetschi

Giuseppe Cecere

Sandra Steiner

Karlheinz Baumann

Sergey Paushkin

Chunshi Li

Parichehr Malherbe

Jérôme Charles Sarie

Song Xiao Huang

Xinlan Aloise Ford Cook

Nikolai Naryshkin

Georg Jaeschke

Michael Patrick Dillon

Heinz Stadler

Torsten Hoffmann

Annick Goergler

Kurt Puentener

Rosa Maria Rodriguez-Sarmiento

Fabienne Hoffmann-Emery

Christian Schnider

Friedrich Metzger

Daniela Krummenacher

Hiroo Koyama

Patrick Williamson

Anthony A Yurpoff

Nicole Risher

Joanie Marie Caroon

Stefan Berchtold

Björn Bartels

Robert Jack Gillespie

Song Huang

Gary Karp

Maria L Weetall

Maria Weetall

The present invention provides compounds of formula (I)

Compounds for treating spinal muscular atrophy

Provided herein are compounds of Formula (I): and forms thereof, wherein w, w, w, w, w, wand ware as defined herein, including compositions thereof and uses therewith for treating spinal muscular atrophy.

The present invention relates to compounds of formula (I), wherein R is hydrogen or halogen, wherein R may be different if n=2 or 3; n is 1, 2 or 3; (II) is a disubstituted bicyclo[1,1,1]pentane or bicyclo[2,2,2]octane as defined below: (III) or (IV); or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Triazolo-azepine derivatives

The invention provides new pyrimidine compounds having the general formula (I), wherein R, R, R, n, and X are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds. 

Pyrimidine derivatives

The present invention relates to a compound of formula (I) wherein Ar is (II) or (II); R is CHor OCH; or a pharmaceutically acceptable acid addition salt or a corresponding enantiomer thereof. The compounds are modulators of &#x3b3;-secretase (A &#x3b2;42) and may be useful for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein Ris hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two Roccur; Ris lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH-heterocycloalkyl unsubstituted or substituted by lower alkyl; Ris halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O)-lower alkyl; n is 1, 2 or 3; if n is &#x3e;1, then Rmay be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Phenoxytriazoles

The present invention relates to a FoxM1 gene splicing modifier selected from a compound of formula (I) or of formula (VI) 

Compounds for the treatment of cancer

The present invention relates to a compound of formula I, 1-1 or 1-2 wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, or lower alkoxy substituted by halogen; Rmay be different if n=2 or 3 n is 1, 2 or 3 Ar is a six membered heteroaryl group, selected from wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen or lower alkoxy; Ris hydrogen or halogen; or to a pharmaceutically active acid addition salt thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Bicyclic heteroaryl derivatives

The present invention relates to a compound of formula (I), wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; R may be the same or different, if n=2 or 3; n is 1, 2 or 3; m is 1, 2 or 3; Ar is a five or six membered heteroaryl group, selected from (II), (III), (IV) or (V) wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen or lower alkoxy; Ris hydrogen or halogen; -( ) m-is &#x2014;(CH)&#x2014; or to pharmaceutically active acid addition salts thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-in-farct dementia, dementia pugilistica or Down syndrome. 

Bridged piperidine derivatives

The present invention provides compounds of formula (I) 

The present invention relates to compounds of formula  

Triazolopyridines

Provided herein are compounds of Formula (I): 

The present invention relates to a compound of formula I wherein  The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

Fused pyrimidine derivatives

The present invention relates to compounds of formula I,   The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

The present invention relates to a compound of formula (I), wherein Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy or lower alkoxy substituted by halogen; and Rmay be different if n is 2 or 3; Ris hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, CN, lower alkoxy or lower alkoxy substituted by halogen; X is CH or N; m is 1, 2 or 3; -( )is &#x2014;(CH)&#x2014;; n is 1, 2 or 3; Ar is a five membered heteroaryl group, selected from formula (A), (B), (C), (D), (E) or (F), wherein Ris hydrogen, methyl or chloro; Ris hydrogen or methyl; Ris F, Cl, CHFor CF; or to pharmaceutically active acid addition salts thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Growing community of inventors

Habsheim, France

Hasane Ratni